|
88 |
FDA Issues Revised Guidance On Controlling Nitrosamine Impurities In Pharmaceuticals
|
sureAssist |
2024-12-26 |
711 |
|
87 |
Warning Letter to US Company due to Lack of Product and Process Control
|
sureAssist |
2024-12-26 |
603 |
|
86 |
The IoT edge: Elevating cleanroom monitoring to new heights in the era of Pharma 4.0
|
sureAssist |
2024-12-26 |
631 |
|
85 |
Water system qualification and requalifications: Considerations for microbial identification
|
sureAssist |
2024-12-26 |
883 |
|
84 |
2024 Emerging Trends In Cleanroom Technologies
|
sureAssist |
2024-12-26 |
645 |
|
83 |
Cleanrooms: What is the difference between clean-up period and recovery time?
|
sureAssist |
2024-12-26 |
1,300 |
|
82 |
The most common challenges with a cleanroom
|
sureAssist |
2024-12-26 |
657 |
|
81 |
The Real Cost Of Poor Quality — And What You Should Do About It
|
sureAssist |
2024-12-26 |
612 |
|
80 |
Draft Q&A Guidance Offers Roadmap For Biosimilar Post-approval Changes
|
sureAssist |
2024-12-26 |
595 |
|
79 |
10 points on how the FDA's CDER monitors the Quality of Medicinal Products
|
sureAssist |
2024-12-26 |
573 |
